Exchange: NASDAQ·Updated 09:50 AM EDT
SRPT logo

SRPTSarepta Therapeutics Inc

$16.05
$0.16
(0.99%)
Today
EarningsAug 5
Mkt Cap$1.71B
Vol52,735.00
News
all
press releases
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to...
Business Wire
More News
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space
Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.
Stocktwits
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
Zacks
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next
Analysts at Wolfe Research upgraded Sarepta to ‘Outperform’ from ‘Peer Perform,’ with a price target of $27.
Stocktwits
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sareptas 2024 Employment Commencement Incentive Plan, as a...
Business Wire
SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies
Sarepta is seeking full approval for Amondys 45 and Vyondys 53 in Duchenne muscular dystrophy.
Stocktwits
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45 and VYONDYS 53
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) for...
Business Wire
SRPT or PRTA: Which Is the Better Value Stock Right Now?
SRPT vs. PRTA: Which Stock Is the Better Value Option?
Zacks
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
SRPT vs. ARGX: Which Stock Is the Better Value Option?
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Zacks
<
1
2
...
>

Advertisement|Remove ads.